Wednesday, 21 November 2012

Matthey fine chems perform well in H1

Johnson Matthey reported sales fell 2% to £138m in H1 for its fine chemicals while operating profit rose 14% to £37.2m. Of this, sales in Matthey's API manufacturing business fell 3% to £99m.
Johnson Matthey

Tuesday, 20 November 2012

Sigma-Aldrich is re-aligning its business segments and SAFC will be reamed the SAFC Commercial Markets Business Unit

St Louis Business Journal

EFCG calls for mandatory inspections

The European Fine Chemicals Group (EFCG) has proposed global harmonisation of the rules and regulations governing the manufacture of active APIs. The trade group wants to level the worldwide playing field and ensure the quality of APIs and the medicines containing them. EFCG has proposed mandatory inspections for all global API manufacturers through a mutual recognition agreement (MRA) approach managed by national regulatory authorities to share scarce inspection resources and to avoid duplication of effort.
Pharmaceutical Technology

Recipharm will develop and manufacture a parenteral veterinary product for Vetcare


Fujifilm Diosynth Biotechnologies will manufacture ThromboGenics' Jetrea following FDA approval

Fujifilm Diosynth Biotechnologies

Boehringer Ingelheim will install a laboratory-scale reactor of BaroFold’s Pressure Enabled Manufacturing Technology at its microbial facility in Vienna, Austria

Pharmaceutical Business Review

Cytovance Biologics will manufacture Selexys Pharmaceuticals' SelG1 monoclonal antibody for a phase II clinical study


Boehringer Ingelheim will develop E coli production strains and manufacture toxicology and clinical stage material for Molecular Partners’ DARPin pipeline

Molecular Partners

Wednesday, 14 November 2012

Nitto Denko Avecia to acquire Girindus contract manufacturing business

Nitto Denko Avecia will acquire Girindus America's oligonucleotide and small molecule API contract manufacturing business. Nitto Denko Avecia said the acquisition will allow it to offer customers an expanded range of manufacturing capabilities, as well as a second manufacturing facility for security of supply.
Nitto Denko Avecia

ProBioGen has launched a set of engineered, royalty-free biopharmaceutical CHO production cell lines


Pharma sales flat for DSM

DSM's pharma business reported net sales growth of 1%. However the company said the results were adversely impacted by an uneven delivery pattern at DSM Pharmaceutical Products and by lower margins at DSM Sinochem Pharmaceutical, despite higher volumes. DSM also said it expected business conditions in pharma to remain challenging for the remainder of the year.

Wednesday, 7 November 2012

Kemwell will manufacture biosimilar drugs for Avesthagen

Hindu Business Line

Mixed sales performance at AMRI

AMRI reported a 20% fall in sales to $7.4m for Q3 2012 for its development and small scale manufacturing business. The company reported a 14% rise in sales t $9.3m for large scale manufacturing.

Cambrex reported Q3 2012 sales rising 2.8% to $59.8m


Angel Biotechnology has signed a new deal to expand CTX cells and produce the GMP drug substance batch for ReNeuron

The Scotsman